Targeting myeloid MIF/CD74 axis in metastatic melanoma – mechanisms, prognostication and therapeutic opportunities
Description of the granted funding
Melanoma is the 5th most prevalent form of cancer in Finland, where the inhabitants are predominantly light-skinned. In the advanced stages, melanoma cells spread from the primary site (mostly the skin) via the bloodstream to distant organs. On that stage, surgery, radiotherapy and chemotherapy are less effective. One approach to treat metastatic melanoma is immunotherapy, which boosts the body's natural defences to eliminate the cancer cells. However, several melanoma patients develop mechanisms of resistance to this therapy. We discovered that melanoma cells may produce a factor called MIF, which turn off the body's natural defences, impairing the effectiveness of immunotherapy. In this project, we will validate MIF as a tool to select those patients that are eligible to respond to immunotherapy. For those that are not eligible, we will develop adjuvant strategies that neutralize MIF to restore the body's ability to kill cancer cells, unleashing the full power of immunotherapy.
Show moreStarting year
2020
End year
2026
Granted funding
Related funding decisions
358209
Research costs of Academy Research Fellows(2023)
199 402 €
336530
Research costs of Academy Research Fellows(2020)
300 022 €
Role in consortium of the Academy of Finland
Leader
Funder
Research Council of Finland
Funding instrument
Academy research fellows
Other information
Funding decision number
330876
Fields of science
Biomedicine
Research fields
Biolääketieteet
Identified topics
cancer